ClearSign Technologies suspends ATM prospectus supplement for $10.39 million common stock offering; no shares sold

ClearSign Technologies Corp

On May 26, 2026, ClearSign notified H.C. Wainwright of suspension and termination of the ATM prospectus supplement filed July 17, 2025.
The ATM program allowed sale of up to $10.39 million in common stock, but no shares were sold before suspension.
The ATM Agreement remains in effect, but no sales will occur until a new prospectus supplement is filed.
Termination relates to shelf registration statement Form S-3 (File No. 333-288736) effective July 28, 2025.

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-26-067517
form_type: 8-K
ticker: CLIR
cik: 0001434524
company_name: ClearSign Technologies Corp
filed_at: 2026-05-28T20:19:02+00:00
discovered_at: 2026-05-28T20:20:18.314428+00:00
generated_at: 2026-05-28T20:23:14.417819+00:00
sec_items: ["8.01", "9.01"]
event_type: regulatory
sentiment: neutral
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-26-067517
json_url: https://secwatch.observer/filing/0001104659-26-067517.json
markdown_url: https://secwatch.observer/filing/0001104659-26-067517.md
text_url: https://secwatch.observer/filing/0001104659-26-067517.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1434524/000110465926067517/0001104659-26-067517-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1434524/000110465926067517/tm2615697d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

AIRE

reAlpha regains Nasdaq minimum bid price compliance; matter closed

reAlpha Tech Corp. May 14, 2026, 4:20 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

MSS

Maison Solutions regains Nasdaq minimum bid price compliance; listing continues

Maison Solutions Inc. May 12, 2026, 1:22 PM ET regulatory Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory similar materiality

Filing page SEC filing

XCUR

Exicure gets Nasdaq delinquency notice for late 10-Q; files next day, says compliance regained

EXICURE, INC. June 1, 2026, 3:30 PM ET regulatory Items 7.01, 9.01

same SEC item: 9.01 same event type: regulatory similar materiality

Filing page SEC filing

QUCY

Quantum Cyber regains Nasdaq minimum bid price compliance; deficiency notice closed

Quantum Cyber N.V. May 28, 2026, 4:05 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

LASE

Laser Photonics receives Nasdaq delisting notice for late Q1 2026 10-Q

Laser Photonics Corp May 22, 2026, 5:27 PM ET regulatory Items 3.01, 9.01

same SEC item: 9.01 same event type: regulatory similar materiality

Filing page SEC filing

QNCX

Quince Therapeutics regains Nasdaq listing compliance via equity alternative

Quince Therapeutics, Inc. May 21, 2026, 5:06 PM ET regulatory Items 8.01

same SEC item: 8.01 same event type: regulatory similar materiality

Filing page SEC filing

RICK

RCI Hospitality regains Nasdaq compliance after filing delayed Q1 10-Q

RCI HOSPITALITY HOLDINGS, INC. June 1, 2026, 3:08 PM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory

Filing page SEC filing

OTLK

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days

Outlook Therapeutics, Inc. June 1, 2026, 9:15 AM ET regulatory Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: regulatory

Filing page SEC filing

Source: SEC EDGAR

accession 0001104659-26-067517

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.